A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGM-HF
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2018 According to a Novartis media release, post hoc analysis results were published in the Journal of the American College of Cardiology: Heart failure (JACC-HF).
    • 16 Apr 2018 According to a Novartis media release, post hoc analysis findings were published in The Lancet Diabetes & Endocrinology.
    • 16 Apr 2018 Results published in the Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top